Popular terms

Codon topics
Hydrocodone
Nucleic Acid
Acetaminophen
Carboxylic Acid
Benzoic Acid
Genetically
Recombinant
Amino Acid
Nucleotide
Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitor
Reverse Transcriptase
Antibodies
Base Sequence
Replication

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Codon patents



      

This page is updated frequently with new Codon-related patent applications.




Date/App# patent app List of recent Codon-related patents
06/23/16
20160177283 
 Heterologous expression of termite cellulases in yeast patent thumbnailnew patent Heterologous expression of termite cellulases in yeast
The present invention provides for heterologous expression of termite and termite-associated symbiont cellulases. The cellulases can, for example, be codon-optimized and expressed in yeast host cells, such as the yeast saccharomyces cerevisiae.

06/23/16
20160176889 
 Process for preparing oxycodone compositions patent thumbnailnew patent Process for preparing oxycodone compositions
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/23/16
20160176888 
 Process for preparing oxycodone compositions patent thumbnailnew patent Process for preparing oxycodone compositions
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/23/16
20160175300 
 Process for preparing oxycodone docage form patent thumbnailnew patent Process for preparing oxycodone docage form
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/23/16
20160175299 
 Methods of treating pain patent thumbnailnew patent Methods of treating pain
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/23/16
20160175298 
 Oxycodone dosage forms patent thumbnailnew patent Oxycodone dosage forms
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/16/16
20160168579 
 Encoding text into nucleic acid patent thumbnailEncoding text into nucleic acid
Methods and apparatus are disclosed herein for encoding human readable text conveying a non-genetic message into nucleic acid sequences with a substantially reduced probability of biological impact and decoding such text from nucleic acid sequences. In one embodiment, each symbol of a symbol set of human readable symbols uniquely maps to a respective codon identifier.
Synthetic Genomics, Inc.


06/16/16
20160168263 
 Certain improved human bispecific egfrviii antibody engaging molecules patent thumbnailCertain improved human bispecific egfrviii antibody engaging molecules
We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human egfrviii mutant protein on its surface, and a second arm that specifically engages t cell activation ligand cd3. The polynucleotide is codon optimized for expression in cho cells.
The Government Of The U.s. As Represented By The Secretary Of Health


06/16/16
20160168160 
 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof patent thumbnailBenzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof
The presently described technology provides compositions comprising aryl carboxylic acids and, for example nsaids, chemically conjugated to oxycodone (4,5-α-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.


06/16/16
20160166677 
 Computationally optimized broadly reactive antigens for h1n1 influenza patent thumbnailComputationally optimized broadly reactive antigens for h1n1 influenza
Described herein is the generation of optimized h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h1n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on selected h1n1 viruses isolated from 1918-2012.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


06/09/16
20160158224 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


06/09/16
20160158223 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


06/02/16
20160151361 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


06/02/16
20160151292 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


06/02/16
20160151288 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


05/26/16
20160145603 

Compositions for making random codon-mutant libraries and uses thereof


The present disclosure relates to compositions and methods for randomly introducing codon-mutations in a target nucleic acid molecule and, more particularly, using wild-type and triplet-randomized oligonucleotides to introduce mutations uniformly across a target nucleotide of interest in a controlled fashion and with a low rate of insertions or deletions.. .
Fred Hutchinson Cancer Research Center


05/26/16
20160143323 

Feed additive for swine and feed composition containing the same


A feed additive for swine consists of following ingredients measured by weight: 20-50 sour jujubes, 10-18 radix bupleuri, 6-20 codonopsis pilosula, 10-20 honeysuckles, 10-20 isatis roots, 4-8 anemarrhena asphodeloides, 3-6 liquorice, 10-20 myrica rubra and 30-60 cactuses. The disclosure further provides a feed composition for swine with the above feed additive.

05/26/16
20160143322 

Feed additive for swine and feed composition containing the same


A feed additive for swine consists of following ingredients measured by weight: 20-50 sour jujubes, 10-18 radix bupleuri, 6-20 codonopsis pilosula, 10-20 honeysuckles, 10-20 isatis roots, 3-6 astragalus propinquus, 10-20 myrica rubra and 30-60 cactuses. The disclosure further provides a feed composition for swine with the above feed additive.

05/26/16
20160143321 

Feed additive for swine and feed composition containing the same


A feed additive for swine consists of following ingredients measured by weight: 20-50 sour jujubes, 10-18 radix bupleuri, 6-20 codonopsis pilosula, 10-20 honeysuckles, 10-20 isatis roots, 10-18 chrysanthemums, 6-9 red jujubes, 10-20 myrica rubra and 30-60 cactuses. The disclosure further provides a feed composition for swine with the above feed additive.

05/19/16
20160137699 

Recombinant fusion antigen gene, recombinant fusion antigen protein and subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus


The present invention is directed to a recombinant fusion antigen gene, a recombinant fusion antigen protein and a subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus (prrsv). A recombinant fusion antigen gene, which encodes glycoprotein gp5 with truncated n′-terminal decoy epitope, a linker sequence and membrane protein m, followed by codon optimization, is expressed by a baculovirus expression system in vitro, thereby enhancing a yield of the recombinant fusion antigen protein.
National Pingtung University Of Science And Technology


05/19/16
20160137656 

Processes for making hydrocodone, hydromorphone and their derivatives


Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.. .
Johnson Matthey Public Limited Company


05/19/16
20160137655 

Processes for making hydrocodone, hydromorphone and their derivatives


Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.. .
Johnson Matthey Public Limited Company


05/19/16
20160136156 

Immediate release pharmaceutical compositions comprising oxycodone and naloxone


The present invention pertains to oral immediate release pharmaceutical compositions suitable for treating patients suffering from pain comprising oxycodone and naloxone or their pharmaceutically acceptable salts.. .
Purdue Pharma L.p.


05/19/16
20160136154 

Extended release hydrocodone acetaminophen and related methods and uses thereof


The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof, comprising providing at least one or two dosage form having about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily.
Abbvie Inc.


04/28/16
20160115487 

Cell-free synthetic incorporation of non-natural amino acids into proteins


The present disclosure provides methods for incorporating at least one non-natural amino acid into a polypeptide using a cell-free protein synthesis which includes a cell-free extract and is deficient in endogenous trna. The methods include providing the synthesis system with at least one non-natural amino acid, at least one orthogonal trna and one orthogonal aminoacyl-trna synthetase which aminoacylates the corresponding orthogonal trna with the non-natural amino acid.
Brigham Young University


04/28/16
20160115463 

Codon modified amylase from bacillus akibai


The present invention relates to an isolated synthetic polynucleotide encoding the mature amylase ax856 from bacillus akibai, using codon modified polynucleotide constructs for the expression of the amylase.. .
Novozymes A/s


04/21/16
20160108372 

Pestivirus replicons providing an rna-based viral vector system


Replicons of pestiviruses, in particular replicons of swine fever virus, are engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon contains all the genetic information required for its replication, but lacks essential codons or all codons of at least one of the genes encoding the viral structural proteins e1, e2, ems or c protein, and consequently cannot generate infectious virus particles.

04/21/16
20160106740 

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.

04/21/16
20160106739 

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.

04/21/16
20160106738 

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.

04/14/16
20160102128 

Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells


The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/07/16
20160096875 

Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells


The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/07/16
20160095853 

Use of binders for manufacturing storage stable formulations


The present invention relates to storage stable prolonged release pharmaceutical dosage forms comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof, the manufacture thereof as well as their use for administration to human beings.. .
Purdue Pharma L.p.


03/24/16
20160083763 

Method of random circular permutation by mucp-isc and mucp-issc transposons


A method for designing circular permuted proteins using two engineered mu transposons for easy construction of random circular permuted proteins, the two designed transposons being mucp-isc (mu circular permutation transposon with integrated start codon) and mucp-issc (mu circular permutation transposon with integrated start and stop codon).. .
New York University


03/24/16
20160083748 

Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof


Described herein are synonymously altered gene sequences which express protein in differing levels within secretory as compared to non-secretory target tissue. An expression cassette comprising an open reading frame (orf) for a protein under the control of regulatory sequences which direct expression of the product in cell, which orf has been modified to preferentially increase expression levels in a selected tissue, wherein the modified orf is characterized by a triplet frequency of any one of tables 3-12, 16 or 17..
The Trustees Of The University Of Pennsylvania


03/24/16
20160083462 

Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same


The present invention relates to compositions and methods for creation of vector nucleic acid sequences (e.g., retroviral nucleic acid sequences) that comprise two or more exogenous nucleic acid sequences that encode highly homologous (e.g., identical) polypeptide sequences, yet wherein at least one of the exogenous nucleic acid sequences has been mutated using degenerate codons for purpose of reducing homology between the two or more exogenous nucleic acid sequences while maintaining the encoded polypeptide sequence. Preferred nucleic acid sequences include those encoding multi-chimeric immune receptor (cir) genes.
Roger Williams Hospital


03/24/16
20160083393 

Compounds for treatment of pain


The aspects of the disclosed embodiments are directed to novel compounds, specifically, quaternary ammonium derivatives of tertiary amine containing opioid drug compounds such as hydrocodone, hydromorphone and oxycodone, formulations containing said. Compounds or pharmaceutically acceptable salts thereof, which are capable of providing controlled release of the opioid drug upon administration to a patient in order to treat pain..

03/17/16
20160076052 

Design synthetic genes


The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a gc content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a gc content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes..
Jnc Corporation


03/03/16
20160058680 

Method and apparatus of manufacturing cosmetic products for regenerating skin cell


A method of manufacturing a cosmetic product for regenerating a skin cell including generating a water into a magnetized hexagonal water through a magnetized hexagonal water generator, separating a body fat stem cell from a body skin through a first extractor to extract a natural protein from a culture medium of a stem cell including the adipose-derived stem cell, extracting at least one skin beneficial ingredient from the culture medium of the stem cell through a second extractor, extracting a plant extract from at least one plant of a pomegranate, red ginseng, liquorice, ginseng seed, milk vetch, poria cocos, scutellaria, portulaca oleracea, pleuropterus multiflorus, angelica, angelica tenuissima, coix, codonopsis, morus alba and cucumber, and mixing the magnetized hexagonal water, natural protein, the at least one skin beneficial ingredient and the at least one plant extract through a mixer to manufacture a cosmetic product for regenerating a skin cell.. .
Aphrozone Co., Ltd.


02/25/16
20160051659 

Gene optimized hantaan virus m segment dna vaccine for hemorrhagic fever with renal syndrome


A synthetic, codon-optimized hantaan virus (htnv) full-length m gene open reading frame that consists of a unique nucleotide sequence encoding htnv proteins. This synthetic gene was cloned into a plasmid to form the first optimized htnv full-length m gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized puumala virus (puuv) dna vaccine.
Government Of The United States, As Represented By The Secretary Of The Army


02/11/16
20160039894 

Ptd-smad7 therapeutics


The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described.
The Regents Of The University Of Colorado, A Body Corporate


02/11/16
20160039837 

Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same


Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs..
Johnson Matthey Public Limited Company


02/04/16
20160032254 

Aav vectors produced by insect cells comprising rep52 and rep78 coding sequences with differential codon biases


The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors..
Uniqure Ip B.v.


02/04/16
20160030419 

Once-a-day oxycodone formulations


The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean c24/cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.. .
Purdue Pharma L.p.


01/28/16
20160022805 

Computationally optimized broadly reactive antigens for human and avian h5n1 influenza


Described herein is the generation of optimized h5n 1 influenza ha polypeptides for eliciting a broadly reactive immune response to h5n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on human and avian h5n1 isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


01/21/16
20160017341 

Universal protein overexpression tag comprising ramp function, and application thereof


Provided is a ramp tag capable of solving instability in translation rate resulting from poor compatibility between codons in a foreign gene and a host when expressing a recombinant protein in e. Coli.
Industry Foundation Of Chonnam National University


01/21/16
20160016965 

Novel mixed μ agonist/ δ antagonist opioid analgesics with reduced tolerance liabilities and uses thereof


An opioid narcotics used for the treatment of moderate-to-severe pain that primarily exert their analgesic effects through μ receptors. Although, traditional μ agonists can cause undesired side effects, including tolerance, addition of δ antagonists can attenuate said side effects.
West Virginia University


01/21/16
20160015802 

Compositions and methods to treat aids


Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against hiv are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different hiv envelope glycoproteins.
University Of Massachusetts


01/14/16
20160010111 

Production methods


The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities.
Glaxo Group Limited


01/07/16
20160002616 

Genes with codon mutations encoding xylanase


The present disclosure provides for a polynucleotide sequences encoding a xylanase. More specifically, the present disclosure provides for polynucleotide sequences with codon mutations encoding a xylanase..
Basf Enzymes Llc


12/24/15
20150368622 

Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization


Described herein are rsv polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against rsv..
The United Of America, As Represented By Secretary, Department Of Health And Human Services


12/17/15
20150361158 

Optimized factor viii gene


The present invention provides codon optimized factor viii sequences, vectors and host cells comprising codon optimized factor viii sequences, polypeptides encoded by codon optimized factor viii sequences, and methods of producing such polypeptides.. .
Biogen Ma Inc.


12/10/15
20150353938 

Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr)


This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cdna encoding the rpgr protein.
Applied Genetic Technologies Corporation


12/10/15
20150352136 

Novel aminoglycosides and uses thereof in the treatment of genetic disorders


A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders..
Technion Research & Development Foundation Limited


12/03/15
20150344930 

Codon-optimized recombinant phage and methods of using same


Composition and methods for the detection of one or more target microbe(s) are provided. Compositions of the disclosure include at least one recombinant phage capable of infecting a target microbe, said phage comprising at least a capsid protein sequence, a ribosome binding site, and a codon-optimized marker.
Sample6 Technologies, Inc.


11/26/15
20150335759 

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof


The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride.
Kempharm, Inc.


11/26/15
20150335639 

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited


11/19/15
20150329854 

Method of synthesis of gene library using codon randomization and mutagenesis


Proposed is a method of easily finding an error during analysis of various library sequences of nucleic acid base sequences after synthesizing a gene library using a combination of three nucleic acid base sequences (codon) translated into the same protein. This shows that it is possible to create a gene library having the same protein sequence but different nucleic acid base sequences.
Celemics, Inc.


11/19/15
20150328247 

Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same


Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof..
Ramot At Tel-aviv University Ltd.




Codon topics: Hydrocodone, Nucleic Acid, Acetaminophen, Carboxylic Acid, Benzoic Acid, Genetically, Recombinant, Amino Acid, Nucleotide, Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitor, Reverse Transcriptase, Antibodies, Base Sequence, Replication

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.


2.6829

4410

469398 - 0 - 102